

FACT SHEET: Update on COVID-19 Therapeutics Distribution

The U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR) oversees the procurement and distribution of COVID-19 therapeutics to state and territorial health departments, pharmacies, federally-funded health centers and other partners for free on a weekly basis. ASPR has provided [more than 11 million courses of therapeutics](#) since the fall of 2020, and currently distributes two monoclonal antibody products (Evusheld and Bebtelovimab) and two oral antiviral products (Paxlovid and Lagevrio).

The currently available therapeutics received FDA emergency use authorization in late 2021 / early 2022 and were initially in limited supply. Today, the products are available at more than 50,000 locations nationwide, allowing for rapid administration to patients when they need it. More than 88% of the American population lives within five miles of an active oral antiviral dispensing site. Demand for oral antiviral pills has significantly increased over the past month: there was a 315% increase in Paxlovid courses dispensed and a 200% increase in Lagevrio courses dispensed between April 10 and May 14.

ASPR remains committed to making sure individuals and providers know these products are available and that they can significantly reduce the chances of severe illness and hospitalization. In March, the Biden Administration launched the [Test to Treat initiative](#), which builds on the large existing network of therapeutics administration and dispensing sites. There are more than 2,500 Test to Treat sites nationwide. A [COVID-19 therapeutics locator](#) is available to help people find a Test to Treat site in their community.

ASPR maintains [therapeutics ordering and administration](#) data as reported by sites of administration or dispensing. Data presented covers the entire timeframe of federal distribution of therapeutics.

“The U.S. government has invested in COVID treatments that can significantly reduce the chance of severe illness and hospitalization. These treatments are widely available nationwide. We remain focused on ensuring that patients and providers know where they can find them so they can be used to prevent severe illness and save lives.”

**- HHS Assistant Secretary for Preparedness and Response
Dawn O’Connell**

By the Numbers

Product	Courses Ordered	Courses Administered ¹
Paxlovid ²	2,056,968	668,954
Lagevrio	1,799,949	230,257
Bebtelovimab	347,291	76,103
Evusheld	681,793	253,454

¹Based on 93% of sites reporting as of May 14, 2022

²Includes Paxlovid and Renal Paxlovid

Data Source: HHS – Tiberius